4.2 Review

Recurrent urinary tract infections in women

期刊

INTERNATIONAL UROGYNECOLOGY JOURNAL
卷 26, 期 6, 页码 795-804

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00192-014-2569-5

关键词

Recurrent urinary tract infection; Recurrent UTI; Women; Management; Prevention; Pathway

资金

  1. Medical Research Council [MR/J006742/1] Funding Source: Medline
  2. Medical Research Council [MR/J006742/1] Funding Source: researchfish
  3. National Institute for Health Research [2211] Funding Source: researchfish

向作者/读者索取更多资源

Recurrent urinary tract infections (UTIs) are more common in women and are frequently defined as a parts per thousand yen2 episodes in the last 6 months or a parts per thousand yen3 episodes in the last 12 months. In a primary care setting, 53 % of women above the age of 55 years and 36 % of younger women report a recurrence within 1 year. Thus, management and prevention of recurrent UTI is of utmost significance. This review aims to highlight the latest research in prevention strategies and suggest a management pathway. A search was conducted on MEDLINE, Embase and the Cochrane Database of Systematic Reviews databases for the latest systematic reviews and high-quality randomized controlled trials. Special emphasis was placed on the remit recurrent and strongly adhered to. Furthermore, a Google search was conducted for current guidelines on the management of UTIs. Current prevention strategies include eliminating risk factors that increase the risk of acquiring recurrent UTI and continuous, post-coital and self-initiated antimicrobial prophylaxis. Other prospective preventative strategies, currently under trial, include use of vaccinations, D-mannose and lactobacillus (probiotics). Although risk factors should be identified and addressed accordingly, individualized antibiotic prophylaxis remains the most effective method of management. Non-antibiotic prevention strategies such as cranberry, vitamin C and methenamine salts lack strong evidence to be introduced as routine management options and as alternatives to antibiotics. Based on current evidence and guidelines, a management pathway is recommended. Emerging therapies require further evaluation before they can be recommended.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据